(19)

(11)

EP 4 823 607 A1

(12)

(43) Date of publication: 21.10.2026 Bulletin 2026/43 (21) Application number: 24829244.3 (22) Date of filing: 10.12.2024

(51) International Patent Classification (IPC):  A61K 39/095(2006.01) A61P 31/04(2006.01) (52) Cooperative Patent Classification (CPC): A61K 39/095; A61K 2039/53; A61K 2039/55555; A61K 2039/6075; A61K 2039/627; A61P 31/04; C12N 2310/335; C07K 14/22 (86) International application number: PCT/IB2024/062402 (87) International publication number: WO 2025/126019 (19.06.2025 Gazette 2025/25)

(84) Designated Contracting States: AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC ME MK MT NL NO PL PT RO RS SE SI SK SM TR Designated Extension States: BA Designated Validation States: GE KH MA MD TN (30) Priority: 13.12.2023 US 202363609484 P 18.10.2024 US 202463708841 P (71) Applicant: Pfizer Inc. New York, NY 10001-2192 (US)	(72) Inventors: MCMONAGLE, Patricia Michele Pearl River, New York 10965 (US) SILMON DE MONERRI, Natalie Clare Pearl River, New York 10965 (US) (74) Representative: Pfizer  European Patent Department 23-25 avenue du Docteur Lannelongue 75668 Paris Cedex 14 75668 Paris Cedex 14 (FR)